This ongoing column explores off-label or emerging treatment options, drug development trends, and theoretical concepts in the field of neuroscience. by Anja Srienc, PhD, MD; Puneet Narang, MD; Simrat Sarai,
by Donna Vanderpool, MBA, JD Ms. Vanderpool is Vice President, Risk Management at PRMS, Inc. in Arlington, Virginia. Innov Clin Neurosci. 2018;15(3–4):47–51 Funding: No funding was provided for the preparation
Innov Clin Neurosci. 2018;15(3–4):11–14 Dear Editor: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with a rapid progression, affecting motor neurons in the brain and spinal cord, ultimately leading to
Innov Clin Neurosci. 2018;15(3–4):11–14 Dear Editor: Recently, Iwaku et al1 reported a detailed case of olanzapine-related acute-onset Type 1 diabetes with ketoacidosis.1 They concluded that olanzapine sometimes can cause sudden
Innov Clin Neurosci. 2018;15(3–4):11–14 Dear Editor: Schizophrenia is a chronic and progressive psychiatric disorder requiring long-term treatment with antipsychotics. The use of long-acting injectable antipsychotics (LAI) has been shown to
